GlassScriptPhysician profile
James G Mouser
NPI 1083795892
$3,113.23
in general payments reported to CMS, 2019-2025
28 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $239 · 2021: $595 · 2022: $356 · 2023: $338 · 2024: $698 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.28 | 2022-2025 | |
| Alcon Vision LLC | $353.57 | 2019-2025 | Clareon, Rocklatan, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $309.33 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $227.89 | 2021-2023 | Acthar |
| Kala Pharmaceuticals, INC. | $206.31 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $193.15 | 2020-2025 | |
| Oyster Point Pharma, INC. | $186.52 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $149.36 | 2022-2025 | Miebo, Envista Envy, Vyzulta |
| Amgen INC. | $130.80 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $110.69 | 2022-2023 | |
| Allergan, INC. | $95.13 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $92.74 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.50 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $75.56 | 2024-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $64.95 | 2021-2023 | Tepezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $59.70 | 2023-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Glaukos Corporation | $54.73 | 2023-2024 | Idose |
| Biotissue Holdings INC. | $45.97 | 2022-2024 | |
| New World Medical,INC. | $43.50 | 2023-2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Dompe US, INC. | $39.99 | 2025 | Oxervate |
| Optos, INC. | $38.04 | 2022 | |
| Thea Pharma INC. | $34.01 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $33.47 | 2021 | |
| Harrow Eye, LLC | $26.78 | 2024 | Iheezo, Triesence, Vevye |
| Coopervision INC. | $24.53 | 2020 | |
| Rxsight INC | $21.06 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
| Astellas Pharma US INC | $20.27 | 2024 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mouser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.